1',1'-Dimethylheptyl-Δ-8-tetrahydrocannabinol-11-oic acid: A novel, orally effective cannabinoid with analgesic and anti-inflammatory properties

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 1, 1999, Pages 31-38

  Dajani, Esam Z ^a   Larsen, Kenneth R ^b   Taylor, John ^c   Dajani, Noura E ^a   Shahwan, Thomas G ^a   Neeleman, Stephen D ^b   Taylor, Mark S ^b   Dayton, Merril T ^b   Mir, G Nabi ^c  

^a 1549 RFD   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c Drug Research Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AJULEMIC ACID; CANNABINOID; DICLOFENAC; DIMETHYL SULFOXIDE; DRONABINOL; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MORPHINE SULFATE; NABILONE; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG FORMULATION; HOT PLATE TEST; MOUSE; NOCICEPTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANALGESIA; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CANNABINOIDS; CARCINOMA, BASAL CELL; DIMETHYL SULFOXIDE; DRUG INTERACTIONS; INDOMETHACIN; INJECTIONS, INTRAPERITONEAL; MALE; MICE; PAIN MEASUREMENT; RATS; RATS, WISTAR; STOMACH ULCER; TETRAHYDROCANNABINOL;

EID: 0032821731     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Abood ME and Martin BR (1992) Neurobiology of marijuana abuse. Trends Pharmacol Sci 13:201-206.
2. Abrams WB, Bagdon RE and Zbinden G (1964) Techniques of animal and clinical toxicology, in Animal and Clinical Pharmacologic Techniques in Drug Evaluation (Nodine JH and Seigler PE eds) pp 36-54, Year Book Medical Publishers, Inc, Chicago.
3. Aceto MD, Scates SM, Lowe JA and Martin BR (1996) Dependence on delta-9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 278:1290-1295.
4. Agurell S, Halladin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H and Hollister L (1986) Pharmacokinetics and metabolism of delta-1 tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38:21-43.
5. Bianchi C and Franceschini J (1954) Experimental observations of Haffner's method for testing analgesic drugs. Br J Pharmacol 9:280-284.
6. Burstein SH, Andette CA, Breurr A, Devane WA, Colodner S, Doyle SA and Mechoulam R (1992) Synthetic nonpsychotropic cannabinoids with potent anti-inflammatory, analgesic and leukocyte anti-adhesion activities. J Med Chem 35: 3135-3141.
7. Burstein SH, Friderichs E, Kogel B, Schneider J and Selve N (1998) Analgesic effects of 1′,1′ dimethylheptyl-delta-8, THC 11-oic acid (CT-3) in mice. Life Sci 63:161-168.
8. Buxbaum DM (1972) Analgesic activity of delta-9-tetrahydrocannabinol in the rat and mouse. Psychopharmacologia 25:275-280.
9. 1 receptor antagonist precipitates withdrawal in mice exposed to delta-9-tetrahydrocannabinol. J Pharmacol Exp Ther 285:1150-1156.
10. Dajani EZ and Agrawal NM (1990) Nonsteroidal anti-inflammatory drug-induced gastrointestinal damage in the elderly: Pathogenesis and therapeutic considerations. Intern Med Specialist 11:91-110.
11. Dajani EZ, Bianchi RG, East PF, Bloss JL, Adelatein GW and Yen CH (1977) The pharmacology of SC-27166: A novel anti-diarrheal agent. J Pharmacol Exp Ther 203:512-526.
12. Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38:151-178.
13. Dixon WJ and Massey FJ (1969) Introduction to Statistical Analysis, 3rd ed, pp 193-199, McGraw-Hill, New York.
14. Eddy NB and Leimbach D (1953) Synthetic analgesics. II. Dithienyl-butenyl dithienbutylamine. J Pharmacol Exp Ther 107:385-393.
15. Fride E and Mechoulam R (1993) Pharmacological activity of the cannabinoid agonist anandamide, a brain constituent. Eur J Pharmacol 231:313-314.
16. Gosseline RE, Smith RP and Hodge HC (1984) Clinical Toxicology of Commercial Products (Tracy TM ed) pp II-407, citation 1620, Williams & Wilkins, Baltimore.
17. Haffher F (1929) Prufung Schmerzatillenderr mitel. Dtsch Med Wochenschr 55:731-733.
18. Harris RT, Waters WH and McLendon D (1974) Evaluation of reinforcing capability of delta-9-tetrahydrocannabinol. Psychopharmacology 37:23-29.
19. Irwin S (1964) Drug screening and evaluation of new compounds in animals, in Animal and Clinical Pharmacologic Techniques in Drug Evaluation (Nodine JH and Seigler PE eds) pp 55-68, Yearbook Medical Publishers, Inc, Chicago.
20. Johnson MR, Melvin LS, Althuis TH, Bindra JS, Harbert CA, Milne GM and Weissman A (1981) Selective and potent analgetics derived from cannabinoids. J Clin Pharmacol 21:271S-282S.
21. Johnson MR, Melvin LS and Milne GM (1982) Prototype cannabinoid analgetics, prostaglandins and opiate search for points of mechanistic interaction. Life Sci 31:1703-1706.
22. Jones RT, Benowitz N and Bachman J (1976) Clinical studies of cannabis tolerance and dependence. Ann NY Acad Sci 282:221-239.
23. Lanza FL (1986) A double-blind study of prophylactic effect of misoprostol on lesions of gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects. Dig Dis Sci 31:137S-141S.
24. 2 and cimetidine on hemodynamics and metabolic rate in canine gastric mucosa. Dig Dis Sci 37:1029-1038.
25. Leite JR and Carlini EA (1974) Failure to obtain "cannabis directed behaviorand abstinence behavior in rats chronically treated with cannabis sativa extracts. Psychopharmacology 36:133-145.
26. Litchfield JT and Wilcoxon F (1949) A simplified method of evaluating of dose-effect experiments. J Pharmacol Exp Ther 85:99-113.
27. Martin BR (1995) Marijuana: What it is and what it does, in National Conference on Marijuana Use: Prevention, Treatment and Research. Sponsored by National Institute on Drug Abuse, National Institutes of Health, Center for Substance Abuse Prevention and Center for Substance Abuse Treatment, July 19-20.
28. 50 and its errors by means of logarithmic-probit graph paper. Proc Soc Exp Biol Med 57:261-285.
29. Ohlsson A, Lindgren JE, Whalen A, Agurell S, Hollister LE and Gillespie HK (1980) Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409-416.
30. Perez-Reyes M, Burstein SH, White WR, McDonald SA and Hicks RE (1991) Antagonisms of marihuana effects by indomethacin in humans. Life Sci 48:507-515.
31. Pertwee RG (1991) Tolerance to and dependence on psychotropic cannabinoids, in The Biological Bases of Drug Tolerance and Dependence, pp 231-263, Academic Press, New York.
32. Pryor GT, Husain S and Mitoma C (1977) Influence of fasting on the absorption of and effects of delta-9-THC after oral administration in sesame oil. Pharmacol Biochem Behav 6:331-341.
33. Richardson JD, Kilo S and Hargreaves KM (1998) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111-119.
34. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat J, Caput D, Ferrara P, Soubrie B, Breliere JC and Le Fur G (1994) SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
35. Rubin A, Lemberger L, Warrick P, Crabtree RE and Sullivan H (1977) Physiologic disposition of nabilone, a cannabinoid derivative in man. Clin Pharmacol Ther 22:85-91.
36. Smith FL, Cichewicz D, Martin ZL and Welch SP (1998) The enhancement of morphine antinociception in mice by delta-9 tetrahydrocannabinol. Pharmacol Biochem Behav 60:559-566.
37. Smith PB, Welch SP and Martin BP (1993) Interactions between delta-9-tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther 268: 1381-1387.
38. Sofia RD, Vassar HB and Knobloch LC (1975) Comparative analgesic activity of various naturally occurring cannabinoids in rats and mice. Psychopharmacologia 40:285-295.
39. Young JM and Yee JP (1994) Ketorlac, in Nonsteroidal Anti-inflammatory Drugs: Mechanisms and Clinical Uses (Lewis AJ and Furst DE eds) pp 247-266, Marcel Dekker, New York.
40. Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA and Burstein SH (1998) Dimethylheptyl-THC-11-oic acid: A nonpsychoactive anti-inflammatory agent with a cannabinoid template structure. Arthritis Rheum 41:163-170.